Skip to Content
U.S. National Institutes of Health
Cancer Diagnosis Program Cancer Imaging Program Cancer Therapy Evaluation Program Developmental Therapeutics Program Radiation Research Program Translational Research Program Biometric Research Branch Office of Cancer Complementary and Alternative Medicine
Last Updated: 04/25/2012

New NCI Experimental Therapeutics (NExT) Program Heralds Shortened Timeline for Anticancer Drug Development

Posted: 06/13/07

A new compound, called ABT-888, has passed the first stage of clinical examination using a new model for drug development that promises to shorten -- by up to six to 12 months -- the timeline for taking anticancer drugs from the laboratory to the clinic, according to a team of researchers at the National Cancer Institute (NCI), part of the National Institutes of Health. This result (abstract #3518) was presented June 3, 2007, at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. More…

See Also:

New Approaches to Cancer Drug Development and Clinical Trials: Questions and Answers

NCI Experimental Therapeutics Program (NExT)

Dr. Shivaani Kummar's Phase 0 Presentation at the American Society of Clinical Oncology, June 3, 2007